Elan Corporation, plc
Advanced therapies in neurology, autoimmune diseases and severe pain
Kelly Martin, President & CEO
Shane Cooke, Executive VP, CFO and Head of Elan Drug Technologies
Menghis Bairu, M.D., Senior VP, Head International
James Callaway, Ph.D., Senior VP, Head of Immunotherapy Alzheimer’s Disease Clinical Programs
Nigel Clerkin, Senior VP, Finance and Group Controller
Ivan Lieberburg, M.D., Ph.D., Executive VP and CMO
Dale Schenk, Ph.D., Executive VP and CSO
Kyran McLaughlin, Chairman
Kelly Martin
Floyd Bloom
Shane Cooke
Laurence Crowley
Lars Ekman
Jonas Frick
Ann Maynard Gray
Gary Kennedy
Giles Kerr
Kieran McGowan
William Rohn
Dennis Selkoe
Jeffrey Shames
Treasury Building
Lower Grand Canal Street, Dublin 2
Ireland
Phone: +353-1-709-4000
Fax: +353-1-709-4700
Elan Corporation is focused on medical areas of neuroscience, in which it researches, develops, produces and markets advanced therapies in neurology, autoimmune diseases and severe pain, especially inflammatory and neuropathic pain.
Elan’s markets the following products in the United States:
PRIALT® (ziconnotide intrathecal infusion) used in the treatment of severe pain;
AZACTAM® (aztreonam for injection, USP), MAXIPIME® (cefepime hydrochloride) for injection, both for therapies of infectious diseases;
TYSABRI® indicated for the treatment of multiple sclerosis and Crohn’s disease.
PRIALT® is also approved for sale in the EU
Elan is interested in neurodegenerative disorders, in particular Alzheimer’s disease, and the development of new therapeutical approaches based on immunotherapy, beta and gamma secretase inhibitors. These inhibitors target enzymes whose actions are responsible for the accumulation of the amyloid plaques in the brains of patients suffering from Alzheimer’s disease.
Elan’s research programmes contain several products that are in the developmental and discovery status, including Alzheimer’s immunotherapies in phase I and II clinical trials. Therapies based on beta and gamma secretase research as well as Parkinson’s disease research are in discovery stage.
The application of TYSABRI® (natalizumab) has been extended to indication areas of rheumatoid arthritis in a phase II clinical trial and in a preclinical phase for the indication of autoimmune diseases. The development is partially done in collaboration with Wyeth and Biogen Idec.
The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.
Related patents
- Modified Release Ticlopidine Compositions
- Modified Release Famciclovir Compositions
- Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
- Multiparticulate Modified Release Composition
- Drug Delivery Device
- Pharmaceutical Formulation
- New Pharmaceutical Forms for Administration of Medicaments by Oral Route, with Programmed Release
- Sustained Release Powder and Process for Its Preparation
- Sustained Absorption Pharmaceutical Composition
- Sustained Release Pharmaceuticals Containing Polymer
- Tablet Formulation
- Vorrichtung zur Verabreichung von Arzneimitteln
- Processes for the Preparation of Delayed Action and Programmed Release Pharmaceutical Forms and Medicaments Obtained Thereby
- Arzneimittel-Formulierung
- Medikamentabgabevorrichtung.
- Medicaments with a High Degree of Solubility and Method for Their Production
- Controlled Absorption Pharmaceutical Formulation
- Pharmazeutische Zusammensetzung mit Verzoegerter Abgabe.
- Pharmazeutische Formulierung mit gesteuerter Absorption.
- Controlled Absorption Pharmaceutical Formulation
- Controlled Release Powder
- Small-scale Mill and Method Thereof
- Controlled Release Biodegradable Micro- and Nanospheres Containing Cyclosporin
- Pre-filled Drug-delivery Device and Method of Manufacture and Assembly of Same
- Effervescent Pharmaceutical Formulations Containing Controlled Release Biodegradable Microcapsules
- Formulations and Their Use in the Treatment of Neurological Diseases
- Controlled Release Formulation
- Taste Masked Formulations
- Drug Conversion Device
- Formulations and Their Use in the Treatment of Neurological Diseases
- Oral Morphine Multiparticulate Formulation
- Oral Morphine Multiparticulate Formulation
- Controlled Release Biodegradable Micro- and Nanospheres Containing Cyclosporin
- Needle and Method for Delivery of Fluids
- Medikamentenabgabevorrichtung
- Intradermal Drug Delivery Device
- A Process for the Preparation of a Granulate Suitable to the Preparation of Rapidly Disintegrable Mouth-soluble Tablets
- Pre-filled Drug-delivery Device and Method of Manufacture and Assembly of Same
- Medicament Delivery Device
- Sustained Release Capsule or Tablet Formulation
- Use of Nicotine for the Manufacture of a Kit for the Treatment of Conditions Susceptible to Said Treatment.
- Two-part Device for the Controlled Delivery of an Active Ingredient
- Controlled Release Pharmaceutical Formulation
- Controlled Release Biodegradable Nanoparticles Containing Insulin
- Controlled Release Biodegradable Micro- and Nanospheres Containing Cyclosporin
- Oral Morphine Multiparticulate Formulation
- Controlled Release Powder and Process for Its Preparation
- Controlled Absorption Diltiazem Formulation for Once Daily Administration
- Controlled Release Formlation
- Controlled Release Formulations for Poorly Soluble Drugs
- Two-part Device for the Controlled Delivery of an Active Ingredient
- Retro-inversion Peptides that Target GIT Transport Receptors and Related Methods
- Controlled Release Powder and Process for Its Preparation
- Multiparticulate Bisoprolol Formulation
- Controlled Absorption Diltiazem Formulations
- Arzneimittel mit Gesteuerter Absorption
- Controlled Release Pharmaceutical Compositions Containing Tiagabine
- Formulations and Their Use in the Treatment of Neurological Diseases
- Anti-infective Agents, Process for Their Preparation and Their Use in Therapy
- Controlled Release Pharmaceutical Compositions Containing Tiagabine
- Solvent/Cosolvent Free Microemulsion and Emulsion Preconcentrate Drug Delivery Systems
- Peptides which Enhance Transport across Tissues and Methods of Identifying and Using the Same
- Device and Method of Calibrating and Testing a Sensor for in vivo Measurement of an Analyte
- Controlled Absorption Diltiazem Formulation for Once-daily Administration
- Diltiazem Formulation
- Drug Delivery Device
- Controlled Release Pharmaceutical Formulation
- Tablet Formulation
- Effervescent Pharmaceutical Formulations Containing Controlled Release Biodegradable Microcapsules
- Methods of Calibrating and Testing a Sensor for in vivo Measurement of an Analyte and Devices for Use in such Methods
- Formulations and Their Use in the Treatment of Neurological Diseases
- Two-part Device for the Controlled Delivery of an Active Ingredient
- Antibodies to Peptides that Target GIT Receptors and Related Methods
- Pharmaceutical Formulations with Different Release Times
- Drug Devlivery Kit and Method of Packaging the Same
- Pharmaceutical Composition
- Controlled Absorption Diltiazem Formulations
- Permeation Enhancers
- Automatische Spritze
- Method and System for Enhancing Delivery of an Agent
- Multiparticulate Bisoprolol Formulation
- Pharmaceutical Formulations for Preventing Drug Tolerance.
- Controlled Release Biodegradable Nanoparticles Containing Insulin
- Enhanced Delivery of Nucleic Acid-based Drugs
- Two-part Apparatur for Controlled Release of Effective Component
- Orally Administrable Delivery Device
- Drug Reconstitution and Injection Device
- Method and System for Enhancing Delivery of an Agent
- Intradermal Drug Delivery Device
- Drug Delivery Device
- Controlled Release Formulations for Poorly Soluble Drugs
- Improved Drug Delivery Kit and Method of Packaging the Same
- Absorptive Pharmaceuticals Enhanced in Bioavailability
- Pharmaceutical Formulation
- Controlled Release Formulations for Poorly Soluble Drugs
- Device for Generating a Pulsatile Fluid Drug Flow
- A Method and Device for Entrapping Gas within a Liquid Drug Container
- Drug Delivery Device
- Method of Using Nicotine in the Treatment of Conditions Susceptible to Said Treatment
- Compositions for Reducing Fluctuations in Plasma Concentrations of Large Neutral Amino Acids and Use Thereof in Therapy
- Composition and Method for Enhancing Paracellular Transport across Cell Layers
- Multiparticulate Modified Release Composition
- Multiparticulate Oral Dosage Forms
- Controlled Adsorption Verapamil Containing Pellet
- Automatic Syringe
- Controlled Absorption Pharmaceutical Composition
- Medicament Delivery Device
- Pharmaceutical Formulation and Method for the Control of Hypertension and Symptoms of Angina over a Twenty-four Period
- Peyers's Patch and/or M-celle Targeting Ligands
- Subcutaneous Drug Delivery Device with Improved Filling System
- Multiparticulate Modified Release Composition
- Peptides which Enhance Transport across Tissues and Methods of Identifying and Using the Same
- Controlled Release Formulations for Poorly Soluble Drugs
- Cartridge-based Drug Delivery Device
- Anaylte-controlled Liquid Delivery Device and Analyte Monitor
- Preparation of Controllable Release of Slightly Coluble Drugs Contained Therein
- Oral Morphine Multiparticulate Formulation
- Composition and Method for Enhancing Paracellular Transport Across Cell Layers
- Methods of Measuring the Concentration of an Analyte in a Subject
- Controlled Absorption Diltiazen Formulation for Once-daily Administration
- Multiparticulate Controlled Release Selective Serotonin Reuptake Inhibitor Formulations.
- Agent for Use in the Prevention, Conrol or Reversal of Hypertension
- Drug Delivery Device
- Sustained Release Drug Delivery System
- Needle for Subcutaneous Delivery of Fluids
- Drug Delivery Compositions Suitable for Intravenous Injection
- Methods of Treatment with Diltiazem Formulations
- Multiparticulate Modified Release Composition
- Drug Delivery Kit and Method of Packaging the Same
- Controlled Absorption Pharmaceutical Composition
- Peptides which Enhance Transport Across Tissues and Methods of Identifying and Using the Same
- Composition and Method for Enhancing Paracellular Transport Across Cell Layers
- Controlled Absorption Naproxen Formulation for Once-daily Administration.
- Needle for Subcutaneous Delivery of Fluids
- Oral Morphine Multiparticulate Formulation
- Formulations and Their Use in the Treatment of Neurological Diseases.
- Two-part Device for the Controlled Delivery of an Active Ingredient
- Controlled Release Formulations for Poorly Soluble Drugs
- A Process for the Preparation of a Granulate Suitable to the Preparation of Rapidly Disintegrable Mouth-soluble Tablets
- Peptides which Enhance Transport Acrtoss Tissues and Methods of Identifying and Using the Same
- Retro-inversion Peptides that Target GIT Transport Receptors and Related Methods
- Multiparticulate Modified Release Composition
- Antibodies to Peptides that Target GIT Receptors and Related Methods
- Fluessige Dispersion zur Oralen Verabreichung
- Controlled Release Amino Pyridine Apparatus
- Medicament Delivery Device
- Intradermal Drug Delivery Device
- Screening Method and Application Method Thereof
- Isostearic Acid Salts as Permeation Rnhancers
- Automatic Syringe